Cardionomic is developing a transformative, minimally invasive neuromodulation therapy addressing a large unmet need in the acute decompensated heart failure (ADHF) population. The company’s catheter-based system electrically stimulates select cardiac nerves which increases left ventricular contractility (inotropy) and cardiac output without increasing heart rate or inducing the negative systemic effects seen with pharmacological inotropes. Following multiple animal studies which established the proof of concept, Cardionomic has successfully demonstrated human feasibility of the physiological mechanism behind its device in multiple studies.